資源描述：
《濾泡性輔助t細胞及濾泡性調(diào)節(jié)t細胞在結(jié)直腸癌患者外周血中的表達及其臨床意義》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在學術(shù)論文-天天文庫。
1、授予單位代碼10089學號或申請?zhí)?0123188HebeiMedicalUniversity碩士學位論文專業(yè)學位濾泡性輔助T細胞及濾泡性調(diào)節(jié)T細胞在結(jié)直腸癌患者外周血中的表達及其臨床意義研究生：趙召龍導師：李中信教授專業(yè)：外科學2015年3月河北醫(yī)科大學學位論文使用授權(quán)及知識產(chǎn)權(quán)歸屬承諾本學位論文在導師（或指導小組）的指導下，由本人獨立完成。本學位論文研究所獲得的研究成果，其知識產(chǎn)權(quán)歸河北醫(yī)科大學所有。河北醫(yī)科大學有權(quán)對本學位論文進行交流、公開和使用。凡發(fā)表與學位論文主要內(nèi)容相關(guān)的論文，第一署名為單位河北醫(yī)科大學
2、，試驗材料、原始數(shù)據(jù)、申報的專利等知識產(chǎn)權(quán)均歸河北醫(yī)科大學所有。否則，承擔相應法律責任。研究生簽名左導師簽章:t二級學院領(lǐng)導蓋章：>/淨)?驗臺,河北醫(yī)科大學研究生學位論文獨創(chuàng)性聲明本論文是在導師指導下進行的研究工作及取得的研宄成果，除了文中特別加以標注和致謝等內(nèi)容外，文中不包含其他人己經(jīng)發(fā)表或撰寫的研究成果，指導教師對此進行了審定。本論文由本人獨立撰寫，文責自負。研宄生簽名:導師簽章月7SX0日lo)S目錄中文摘要··················································
3、·······························1英文摘要·················································································4英文縮寫·················································································8研究論文濾泡性輔助T細胞及濾泡性調(diào)節(jié)T細胞在結(jié)直腸癌患者外周血中的表達及其臨床意義前言·············
4、····································································9材料與方法······································································10結(jié)果···············································································13附圖·····························
5、··················································15附表···············································································20討論···············································································21結(jié)論········································
6、·······································24參考文獻·········································································25綜述濾泡性輔助T細胞（Tfh）與人相關(guān)疾病的研究·················30致謝·····················································································53個人簡歷····
7、···········································································54中文摘要濾泡性輔助T細胞及濾泡性調(diào)節(jié)T細胞在結(jié)直腸癌患者外周血中的表達及其臨床意義摘要背景：結(jié)直腸癌是全世界發(fā)病率排名第三的惡性腫瘤，每年有超過100萬患者確診為結(jié)直腸癌。傳統(tǒng)治療手段（手術(shù)，化療，放療，靶向治療）療效不理想。除了腫瘤本身的機制外，腫瘤微環(huán)境特別是炎癥反應、免疫反應與腫瘤的進展甚至放化療、靶向藥物抵抗有關(guān)?？梢哉f,腫瘤免疫治療的時代已經(jīng)到來。事實上
8、越來越多的證據(jù)表明,在預防腫瘤的發(fā)生、生長和轉(zhuǎn)移擴散中免疫系統(tǒng)扮演重要的角色。+對于CD4T淋巴細胞亞群的研究是近年來免疫學研究的一個熱點。+Tfh作為CD4T淋巴細胞亞群的一種，是近年來研究發(fā)現(xiàn)的一種特殊的輔助性T細胞，表達CXCR5的Tfh細胞在CXCL13的趨化下，被募集到淋巴濾泡，參與誘導B細胞的分化及生發(fā)中心的形成，通過產(chǎn)生IL-21等細胞因子以及
